Category: Policy & Public Affairs

We’ve united with 12 leading cancer charities to respond to the government’s Timms Review into Personal Independence Payments (PIP).

We welcome a new Scottish Parliament, share an update on recent activity in Scotland as well as our call for a National Brain Tumour Strategy.

While the newly elected Members of the Senedd settle into their roles and Plaid Cymru form the next government, we’re taking stock of the progress made in improving brain tumour care and outcomes across Wales. This new government brings a critical opportunity to shift the dial for brain tumour care, diagnosis, treatment and research in Wales.

In an article for Open Access Government, published in April 2026, Dr Simon Newman explains how we’re trying to help give more people better access to clinical trials.

In a positive end to Brain Tumour Awareness Month 2026, we are pleased that NICE has approved vorasidenib to treat some types of brain tumours.

Our new report explains how to unlock brain tumour innovation in the UK and the systemic barriers holding it back.

We’re delighted to share the news that vorasidenib has been approved by the Scottish Medicines Consortium to treat some low grade gliomas.

We’re celebrating the news that the Rare Cancers Act has now become law and the transformative potential this has for the brain tumour community.

Following a consultation by the Department of Health and Social Care, in which we fed back your experiences of brain tumours, we welcome the publication of the National Cancer Plan for England and its explicit focus on rare and less survivable cancers, including brain tumours.

In August 2025, Mark joined The Brain Tumour Charity’s Scottish Steering Committee. Here he shares why he joined the Committee and what he hopes can be achieved.

We provide an update on the latest developments surrounding the appraisal process related Vorasidenib.

Despite the disappointing draft guidance published by NICE, there’s still hope that vorasidenib will be available through the NHS in England.

We provide an update on the Scottish Steering Committees decided ambitions and objectives that members will seek to achieve.

In this post we provide an update on recent Campaigns activity including on the Rare Cancers Bill and the NIHR-funded National Brain Tumour Research Consortium.

Following our previous statement in April 2025, we share the latest update on activity linked to the National Brain Tumour Research Consortium

This week we hosted a roundtable with representatives from the life sciences sector to begin to understand potential barriers to innovation across the UK.

Dordaviprone, also known as ONC201, offers new hope for treating H3 K27M-Mutated Diffuse Midline Glioma. But, there’s a long way to go before it’s ready for use on the NHS.

We explore the upcoming National Cancer Plan targets and their potential impact on survival gaps in cancer treatment.

NHS Scotland has published updated referral guidance for suspected cancers – including brain. We share information on some of the key changes that have been made.

We’ve broken down what the proposed reforms were, what’s changed, and what it means for our community.

The Rare Cancers Bill is at risk of falling – we urge supporters to get in touch with their MP to ensure it progresses.

Following the launch of the UK Government’s 10 Year Health Plan, we analyse some of the key announcements that may impact the brain tumour community.

“The Rare Cancers Bill, led by Scott Arthur MP, has passed Committee Stage – bringing hope to those affected by rare and less survivable cancers, including brain tumours.”

If we’re going to improve survival rates and quality of life for people with a brain tumour, research must be shaped by those who are eligible to take part.